SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 867-872

  Miyoshi, Kei ^a   Sato, Norihiro ^a   Ohuchida, Kenoki ^a   Mizumoto, Kazuhiro ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Pancreatic cancer; Prognosis; SPARC

Indexed keywords

MESSENGER RNA; OSTEONECTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CARDIOVASCULAR SYSTEM; DEPTH PERCEPTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROTEIN EXPRESSION; TISSUE PREPARATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; OSTEONECTIN; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 77951050647     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C and Neoptolemos JP: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82: 111-115, 1995.
3. Jendraschak E and Sage EH: Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. Semin Cancer Biol 7: 139-146, 1996.
4. Yan Q and Sage EH: SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 47: 1495-1506, 1999.
5. Bradshaw AD and Sage EH: SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 107: 1049-1054, 2001.
6. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR and Sage EH: Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 111: 487-495, 2003.
7. Yamashita K, Upadhay S, Mimori K, Inoue H and Mori M: Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 97: 2412-2419, 2003.
8. Watkins G, Douglas-Jones A, Bryce R, Mansel RE and Jiang WG: Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 72: 267-272, 2005.
9. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, Hruban RH and Goggins M: SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22: 5021-5030, 2003.
10. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C and Goggins M: Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25: 319-325, 2007.
11. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK and Kim H: Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 121: 567-575, 2007.
12. Tai IT, Dai M, Owen DA and Chen LB: Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 115: 1492-1502, 2005.
13. Kato Y, Nagashima Y, Baba Y, Kawano T, Furukawa M, Kubota A, Yanoma S, Imagawa-Ishiguro Y, Satake K, Taguchi T, Hata R, Mochimatsu I, Aoki I, Kameda Y, Inayama Y and Tsukuda M: Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. Int J Mol Med 16: 263-268, 2005.
14. Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, Dexter T, Davies S, Bulmer K, Ford E, Parry S, Budroni M, Palmieri G, Neville AM, O'Hare MJ and Lakhani SR: Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 64: 3037-3045, 2004.
15. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG and Coman WB: Novel markers for poor prognosis in head and neck cancer. Int J Cancer 113: 789-797, 2005.
16. Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, Kanayama HO and Kagawa S: Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 166: 2495-2499, 2001.
17. Wang CS, Lin KH, Chen SL, Chan YF and Hsueh S: Overexpression of SPARC gene in human gastric carcinoma and its clinicopathologic significance. Br J Cancer 91: 1924-1930, 2004.
18. Massi D, Franchi A, Borgognoni L, Reali UM and Santucci M: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 30: 339-344, 1999.
19. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM and Whelan S (eds.): International Classification of Diseases for Oncology. 3rd Geneva, Switzerland Edition: World Health Organization, 2000.
20. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D and Morrow M (eds.): AJCC Cancer Staging Manual. 6th Edition. New York: Springer-Verlag, pp. 157-164, 2002.
21. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, Matsumoto K, Nakamura T and Tanaka M: Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 64: 3215-3222, 2004.
22. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R, Hoelscher AH, Danenberg KD, Prenzel KL and Danenberg PV: High expression of HIF1α is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 10: 674-679, 2008.
23. Bloomston M, Ellison EC, Muscarella P, Al-Saif O, Martin EW, Melvin WS and Frankel WL: Stromal osteonectin overexpression is associated with poor outcome in patients with ampullary cancer. Ann Surg Oncol 14: 211-217, 2007.
24. Guweidhi A, Kleeff J, Adwan H, Giese NA, Wente MN, Giese T, Buchler MW, Berger MR and Friess H: Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 242: 224-234, 2005.
25. Jacob K, Webber M, Benayahu D and Kleinman HK: Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 59: 4453-4457, 1999.
26. Briggs J, Chamboredon S, Castellazzi M, Kerry JA and Bos TJ: Transcriptional up-regulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 21: 7077-7091, 2002.
27. Schultz C, Lemke N, Ge S, Golembieski WA and Rempel SA: Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62: 6270-6277, 2002.
28. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S, Goldsmith CM, Piper JT, Vostal JG, Harms JF, Welch DR and Kleinman HK: Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 65: 7370-7377, 2005.
29. Said N and Motamed K: Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 167: 1739-1752, 2005.
30. Ryu B, Jones J, Hollingsworth MA, Hruban RH and Kern SE: Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res 61: 1833-1838, 2001.
31. Mantoni TS, Schendel RR, Rodel F, Niedobitek G, Al-Assar O, Masamune A and Brunner TB: Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther 7: 1806-1815, 2008.